Sustained Release Injectables and Less Frequent Dosing

The ability to formulate injectable drugs to increase the duration of efficacy for a given dose and simultaneously reduce the dosing frequency addresses several important health care issues. Less frequent dosing is believed to improve patient safety, reduce the incidence of injection site complications and improve compliance with drug protocols. Sustained release formulations mitigate the bolus effect at the time of injection, and thus have a salutary influence on drug side effects. All of these advantages, along with the need for fewer patient caregiver visits (for practitioner-administered drugs) have a positive, downward impact on overall healthcare costs. Currently approved sustained release injectables rely on a spectrum of branded formulation technologies to modulate the drug’s release profile post-injection. Typically off-patent or generic drugs, they include drug therapies for almost a dozen major therapeutic segments, including neurological conditions, metabolic diseases, oncology, pain management and reproductive health. As the incidence and prevalence of chronic illnesses increases with the aging population, the attraction and interest in sustained release injectables will increase.

Publication Date: February 2010

Summary of Contents

Executive Summary

Injectable Drug Delivery Market Dynamics

The Trend toward Self-Administration

Shifting Demographics

Injectable Drug Formulation Technology

Innovation in Injectable Device Designs

Therapeutic Demand Drivers

Competitive Landscape

Risk Factors

Sustained Release Injectables - Branded Formulation Platforms

Biodegradable Polymers

PEG

PLG/PLA/PLGA

Polyether ester

Dextran

Fusion Proteins

Liposomes

Sucrose acetate isobutyrate

Supercritical Fluid

Analysis of FDA Approved Sustained Release Injectables

cytarabine

goserelin acetate

Interferon

lanreotide acetate

leuprolide acetate

morphine

naltrexone

olanzapine

risperidone

paliperidone palmitate

octreotide acetate

triptorelin pamoate

Development-Stage SR Injectable Drug Candidate Assessment

Antivirals

Hormones

Immune Modulators

Incretin Mimetics

Local Anesthetics

Opioid Antagonists

Psychotropics

Antineoplastics

Sustained Release Injectables – Therapeutic Sector Impact Analysis & Forecasts

Addiction

Autoimmune Diseases

Diabetes

Infectious Disease

Metabolic Diseases

Neurology

Oncology

Pain Management

Reproductive Health

Market Factors and Commercialization Strategies

Sustained Release Injectables - Company Profiles

About Our Reports

Our reports are carefully researched and written to provide timely and insightful analysis of key factors and developments shaping the commercial marketplace. The focused nature of our publications is designed to allow readers to identify emerging demand and growth opportunities in selected markets. Numerous charts, tables and graphs complement the text, with evaluations and assessments of current and probable future market developments, technology issues and business factors - information necessary to compete effectively in the global marketplace.